NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
P Greenberg, Richard M. Stone, Yasmin Abaza, Aref Al‐Kali, Sarah Anand, Brian Ball, John M. Bennett, Uma Borate, Andrew M. Brunner, Wanxing Chai‐Ho, Peter Curtin, Amy E. DeZern, Karin Gaensler, Zhubin Gahvari, Guillermo Garcia-Manero, Elizabeth A. Griffiths, Tamanna Haque, Meagan A. Jacoby, Brian A. Jonas, Sioḃán Keel, Rashmi Khanal, Ashwin Kishtagari, Yazan F. Madanat, Lori J. Maness, Shannon R. McCurdy, Christine M. McMahon, Olatoyosi Odenike, Afaf Osman, Vishnu Reddy, David A. Sallman, Hamid Sayar, Rory M. Shallis, Abhay Singh, Tiffany Tanaka, Swapna Thota, Emily Kovach, Jamie Nguyen, Cindy Hochstetler
Abstract
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.